US4292315A
(en)
*
|
1977-12-30 |
1981-09-29 |
Nichols Vorys |
Follicular phase estrogen or progestin with physiologic estrogen/progestin luteal phase replacement drug delivery system
|
NL8001593A
(nl)
*
|
1980-03-18 |
1981-10-16 |
Akzo Nv |
Meerfasisch combinatiepreparaat voor orale anticonceptie.
|
DE3029726A1
(de)
*
|
1980-08-06 |
1982-02-25 |
Werner Dr.med. 4400 Münster Steinschulte |
Postkoitale kontrazeptiva mit norgestrel oder levonorgestrel
|
US4425339A
(en)
|
1981-04-09 |
1984-01-10 |
Syntex (U.S.A.) Inc. |
Treatment of menopausal symptoms
|
US4390531A
(en)
*
|
1981-08-10 |
1983-06-28 |
Syntex Pharmaceuticals International Ltd. |
Method of contraception using peak progestogen dosage
|
AU582540B2
(en)
*
|
1983-08-05 |
1989-04-06 |
Pre Jay Holdings Ltd. |
A method of hormonal treatment of perimenopausal, menopausal and post-menopausal disorders and multi-preparation pack therefor
|
US4826831A
(en)
*
|
1983-08-05 |
1989-05-02 |
Pre Jay Holdings Limited |
Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens
|
DE3347125A1
(de)
*
|
1983-12-22 |
1985-07-11 |
Schering AG, 1000 Berlin und 4709 Bergkamen |
Mehrstufenkombinationspraeparat und seine verwendung zur oralen kontrazeption
|
US4610687A
(en)
*
|
1984-08-06 |
1986-09-09 |
Board Of Trustees Operating Michigan State University |
Method for breeding control in female bovines
|
US5010070A
(en)
*
|
1987-06-15 |
1991-04-23 |
Warner-Lambert Company |
Graduated estrogen contraceptive
|
US4816257A
(en)
*
|
1985-09-20 |
1989-03-28 |
Research & Education Institute, Harbor-Ucla Medical Center Inc. |
Method for producing an in vivo environment suitable for human embryo transfer
|
US4958736A
(en)
*
|
1986-03-18 |
1990-09-25 |
Gynex, Inc. |
Package for oral contraceptive tablet
|
US4762717A
(en)
*
|
1986-03-21 |
1988-08-09 |
The General Hospital Corporation |
Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use as a contraceptive
|
IE61236B1
(en)
†
|
1986-07-15 |
1994-10-19 |
American Home Prod |
Combination dosage form for pre-menopausal women
|
US5108995A
(en)
*
|
1987-09-24 |
1992-04-28 |
Jencap Research Ltd. |
Hormone preparation and method
|
US5276022A
(en)
*
|
1987-09-24 |
1994-01-04 |
Jencap Research Ltd. |
Hormone preparation and method
|
GB2217988B
(en)
*
|
1988-04-11 |
1992-04-01 |
Gould Leonard W |
Regimen for increasing bone density in humans
|
IE67345B1
(en)
*
|
1991-03-12 |
1996-03-20 |
Akzo Nv |
Low dose dry pharmaceutical preparations
|
US6407082B1
(en)
*
|
1996-09-13 |
2002-06-18 |
New Life Pharmaceuticals Inc. |
Prevention of ovarian cancer by administration of a vitamin D compound
|
US5747480A
(en)
*
|
1996-05-08 |
1998-05-05 |
American Home Products Corporation |
Oral contraceptive
|
US5858405A
(en)
*
|
1996-07-26 |
1999-01-12 |
American Home Products Corporation |
Oral contraceptive
|
US5888543A
(en)
*
|
1996-07-26 |
1999-03-30 |
American Home Products Corporation |
Oral contraceptives
|
US6451778B1
(en)
|
1996-07-26 |
2002-09-17 |
Wyeth |
Oral contraceptive
|
WO1998004268A1
(en)
*
|
1996-07-26 |
1998-02-05 |
American Home Products Corporation |
Oral contraceptive
|
US6479475B1
(en)
|
1996-07-26 |
2002-11-12 |
Wyeth |
Oral contraceptive
|
US6028064A
(en)
|
1996-09-13 |
2000-02-22 |
New Life Pharmaceuticals Inc. |
Prevention of ovarian cancer by administration of progestin products
|
US6511970B1
(en)
|
1996-09-13 |
2003-01-28 |
New Life Pharmaceuticals Inc. |
Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
|
US6765002B2
(en)
|
2000-03-21 |
2004-07-20 |
Gustavo Rodriguez |
Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium
|
US6034074A
(en)
|
1996-09-13 |
2000-03-07 |
New Life Pharmaceuticals Inc. |
Prevention of ovarian cancer by administration of a Vitamin D compound
|
US20050038006A1
(en)
*
|
1998-12-23 |
2005-02-17 |
Shangold Gary A. |
Triphasic oral contraceptive
|
US6214815B1
(en)
|
1998-12-23 |
2001-04-10 |
Ortho-Mcneil Pharmaceuticals, Inc. |
Triphasic oral contraceptive
|
US7459445B2
(en)
*
|
2000-03-10 |
2008-12-02 |
Duramed Pharmaceuticals, Inc. |
Estrogenic compounds and topical pharmaceutical formulations of the same
|
US7989436B2
(en)
|
2003-07-23 |
2011-08-02 |
Duramed Pharmaceuticals, Inc. |
Estrogenic compounds and pharmaceutical formulations comprising the same
|
US6660726B2
(en)
|
2000-03-10 |
2003-12-09 |
Endeavor Pharmaceuticals |
Estrogenic compounds, pharmaceutical compositions thereof, and methods of using same
|
US6855703B1
(en)
|
2000-03-10 |
2005-02-15 |
Endeavor Pharmaceuticals |
Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds
|
US20050113351A1
(en)
*
|
2000-03-21 |
2005-05-26 |
Rodriguez Gustavo C. |
Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
|
US20040176336A1
(en)
*
|
2000-03-21 |
2004-09-09 |
Rodriguez Gustavo C. |
Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
|
US20010044431A1
(en)
*
|
2000-03-21 |
2001-11-22 |
Rodriguez Gustavo C. |
Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
|
DE10045380A1
(de)
*
|
2000-09-14 |
2002-04-04 |
Schering Ag |
Verfahren zur Kontrazeption und dessen Darreichungsform
|
US6992075B2
(en)
*
|
2003-04-04 |
2006-01-31 |
Barr Laboratories, Inc. |
C(14) estrogenic compounds
|
CA2521471A1
(en)
*
|
2003-04-11 |
2004-10-28 |
Barr Laboratories, Inc. |
Methods of administering estrogens and progestins
|
DE102004019743B4
(de)
|
2004-04-20 |
2008-11-27 |
Bayer Schering Pharma Aktiengesellschaft |
Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens
|
WO2006084082A1
(en)
*
|
2005-02-03 |
2006-08-10 |
Duramed Pharmaceuticals, Inc. |
Compositions of unconjugated estrogens and methods for their use
|
US8153616B2
(en)
|
2005-10-17 |
2012-04-10 |
Bayer Pharma Aktiengesellschaft |
Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
|
EP1930010A1
(de)
|
2006-10-20 |
2008-06-11 |
Bayer Schering Pharma Aktiengesellschaft |
Verwendung von Estradiolvalerat oder 17ß-Estradiol in Kombination mit Dienogest zur oralen Therapie für den Erhalt und/oder die Steigerung der weiblichen Libido
|
US11376263B2
(en)
|
2020-10-08 |
2022-07-05 |
Fortress Biotech, Inc. |
Cyproterone acetate compositions and uses thereof
|